DE212015000076U1 - Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin - Google Patents

Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin Download PDF

Info

Publication number
DE212015000076U1
DE212015000076U1 DE212015000076.1U DE212015000076U DE212015000076U1 DE 212015000076 U1 DE212015000076 U1 DE 212015000076U1 DE 212015000076 U DE212015000076 U DE 212015000076U DE 212015000076 U1 DE212015000076 U1 DE 212015000076U1
Authority
DE
Germany
Prior art keywords
astaxanthin
molecular weight
composition
oil
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE212015000076.1U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Nutraceuticals LLC
Original Assignee
US Nutraceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/217,515 external-priority patent/US9238043B2/en
Priority claimed from US14/645,805 external-priority patent/US9402857B2/en
Application filed by US Nutraceuticals LLC filed Critical US Nutraceuticals LLC
Publication of DE212015000076U1 publication Critical patent/DE212015000076U1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/655—Aquatic animals other than those covered by groups A61K35/57 - A61K35/65
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Oceanography (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE212015000076.1U 2014-03-18 2015-03-16 Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin Active DE212015000076U1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/217,515 US9238043B2 (en) 2009-07-23 2014-03-18 Composition and method to alleviate joint pain using algae based oils
US14/217,515 2014-03-18
US14/645,805 US9402857B2 (en) 2009-07-23 2015-03-12 Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US14/645,805 2015-03-12
PCT/US2015/020678 WO2015142707A1 (fr) 2014-03-18 2015-03-16 Composition et procédé pour soulager la douleur articulaire au moyen d'acide hyaluronique de faible poids moléculaire et d'astaxanthine

Publications (1)

Publication Number Publication Date
DE212015000076U1 true DE212015000076U1 (de) 2016-12-06

Family

ID=53008840

Family Applications (1)

Application Number Title Priority Date Filing Date
DE212015000076.1U Active DE212015000076U1 (de) 2014-03-18 2015-03-16 Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin

Country Status (3)

Country Link
KR (1) KR20160144388A (fr)
DE (1) DE212015000076U1 (fr)
WO (2) WO2015142707A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105581332A (zh) * 2015-12-31 2016-05-18 石家庄中硕药业有限公司 一种具有改善皮肤水分和抗氧化功能的组合物及制备方法
CZ2016340A3 (cs) * 2016-06-07 2017-05-31 Mikrobiologický Ústav Av Čr V.V.I. Produkční kmen řasy Monoraphidium sp. pro produkci olejů s obsahem polynenasycených mastných kyselin, způsob produkce těchto olejů a použití tohoto produkčního kmene pro průmyslovou výrobu těchto olejů
AU2018392997A1 (en) * 2017-12-22 2019-08-15 Pharmalink International Limited Lipid combinations
WO2021156385A1 (fr) 2020-02-04 2021-08-12 Wellness Holding B.V. Composition lipidique comprenant des acides gras oméga-3
CN114366807B (zh) * 2020-10-15 2024-01-12 莱博瑞辰生物医药科技有限公司 一种用于预防和/或治疗骨关节炎的组合物

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6025327A (en) 1997-08-08 2000-02-15 Biocell Technology, Llc Hydrolyzed collagen type II and use thereof
US6780841B2 (en) 2001-11-13 2004-08-24 Biocell Technology, Llc Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US6806259B2 (en) 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
US20040234587A1 (en) 2001-07-27 2004-11-25 Fotini Sampalis Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
US20040241249A1 (en) 2001-06-18 2004-12-02 Tina Sampalis Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
US20060183709A1 (en) 2005-02-15 2006-08-17 Ahmad Alkayali Preparation of low molecular weight hyaluronic acid as a food supplement
US20090181114A1 (en) 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Chia seed beverage and related method
US8030037B2 (en) 2007-01-10 2011-10-04 Parry Nutraceuticals, Division Of E.I.D. Parry (India) Ltd. Photoautotrophic growth of microalgae for omega-3 fatty acid production
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8586104B2 (en) 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
US8784904B2 (en) 2008-04-10 2014-07-22 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440760A (en) * 1981-07-27 1984-04-03 Newnham Rex E Food supplement
US6632449B2 (en) * 2001-11-20 2003-10-14 The Procter & Gamble Co. Compositions and kits comprising a defined boron compound and methods of their preparation
GB0314624D0 (en) * 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
US20110117207A1 (en) * 2009-11-17 2011-05-19 U.S. Nutraceuticals, LLC d/b/a Valensa International State of Incorporation: Use of eggshell membrane formulations to alleviate joint pain
US8663704B2 (en) * 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US20150164841A1 (en) * 2012-07-17 2015-06-18 Aker Biomarine Antarctic As Concentration of omega-3 polyunsaturated fatty acids in krill oil
CN102746947B (zh) * 2012-07-18 2013-10-02 福建华尔康生物科技有限公司 一种分离、纯化裂壶藻油中dha和饱和脂肪酸的方法
WO2014014766A1 (fr) * 2012-07-19 2014-01-23 U.S. Nutraceuticals, Llc D/B/A Valensa International Huile de krill et composition d'astaxanthine ayant subi des réactions et méthode associée

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973B1 (fr) 1975-10-17 1989-08-08
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6025327A (en) 1997-08-08 2000-02-15 Biocell Technology, Llc Hydrolyzed collagen type II and use thereof
US20070098808A1 (en) 2001-06-18 2007-05-03 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
US20040241249A1 (en) 2001-06-18 2004-12-02 Tina Sampalis Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
US20040234587A1 (en) 2001-07-27 2004-11-25 Fotini Sampalis Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
US6780841B2 (en) 2001-11-13 2004-08-24 Biocell Technology, Llc Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US6806259B2 (en) 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
US20060183709A1 (en) 2005-02-15 2006-08-17 Ahmad Alkayali Preparation of low molecular weight hyaluronic acid as a food supplement
US8030037B2 (en) 2007-01-10 2011-10-04 Parry Nutraceuticals, Division Of E.I.D. Parry (India) Ltd. Photoautotrophic growth of microalgae for omega-3 fatty acid production
US20090181114A1 (en) 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Chia seed beverage and related method
US8652544B2 (en) 2008-01-11 2014-02-18 U.S. Nutraceuticals, LLC Chia seed composition
US8586104B2 (en) 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
US8784904B2 (en) 2008-04-10 2014-07-22 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8945608B2 (en) 2009-07-23 2015-02-03 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
„Acute Appearance of Fatty Acids in Human Plasma – A Comparative Study Between Polar-Lipid Rich Oil from the Microalgae Nannochloropis Oculata in Krill Oil in Healthy Young Males", veröffentlicht in Lipids in Health and Disease, 2013, 12:102 von Kagan u. a.
„Biosynthesis of Eicosapentaenoic Acid (EPA) in the Fresh Water Eustigmatophyte Monodus Subterraneus (Eustigmatophyceae)", J. Phycol, 38, 745–756 (2002)
Andrewes A. und M. Starr mit dem Titel „(3R,3'R)-Astaxanthin from the Yeast Phaffia Rhodozyma", Phytochemistry, 15: 1009–1011, 1976
Bjorndal u. a., Lipids in Health Disease, 2014, 13:82
Coral-Hinostroza u. a. (2004)
Coral-Hinostroza, G., T. Ytestøyl, B. Ruyter und B. Bjerkeng mit dem Titel „Plasma Appearance of Unesterified Astaxanthin Geometrical E/Z and Optical/S Isomers in Men Given Single Doses of a Mixture of Optical 3 and 3'R/S Isomers of Astaxanthin Fatty Acyl Diesters", Camp. Biochem Phys. C., 139: 99–110, 2004
Fry u. a., Univ. of Memphis Human Performance Laboratories, 2001 und 2004, Berichte 1 & 2
Fry u. a., University of Memphis, Human Performance Laboratories, 2001 und 2004, Berichte 1 und 2
Ghosh P. Guidolin D. Semin Arthritis Rheum., 2002 Aug; 32(1): 10–37; und P. Rooney, M. Wang, P. Kumar und S. Kumar, Journal of Cell Science 105, 213–218 (1993)
Lee u. a., Molecules and Cells 16(1): 97–105, 2003
McKee u. a., J. Biol. Chem. 272, 8013–8018
Mummert u. a., J. of Immunol. 169, 4322–4331
Ohgami u. a., Investigative Ophthalmology and Visual Science 44(6): 2694–2701, 2003
Østerlie, M., B. Bjerkeng und S. Liaan-Jensen mit dem Titel „Plasma Appearance and Distribution of Astaxanthin E/Z und R/S Isomers in Plasma Lipoproteins of Men After Single Dose Administration of Astaxanthin", J. Nutr. Biochem, 11: 482–490, 2000
Renstr⌀m B., G. Borch, O. Skulberg und S. Liaane-Jensen, „Optical Purity of (3S,3'S) Astaxanthin From Haematococcus Pluvialis", Phytochemistry, 20(11): 2561–2564, 1981
Ruff u. a., Eggshell Membrane in the Treatment of Pain and Stiffness from Osteoarthritis of the Knee: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Clinical Study, Clin. Rheumatol (2009) 28: 907–914
Schiedt, K., S. Bischof und E. Glinz mit dem Titel „Metabolism of Carotenoids and in vivo Racemization of (35,3'S)-Astaxanthin in the Crustaecean Penaeus", Methods in Enzymology, 214: 148–168, 1993
Spiller u. a. 2003
Spiller u. a., J. of the Amer. College of Nutrition, 21(5): Oktober 2002
Spiller u. a., J. of the American College of Nutrition 21(5): Oktober 2002
Termeer u. a., Trends in Immunology, Bd. 24, März 2003
Turujman, S, W. Wamer, R. Wei und R. Albert mit dem Titel „Rapid Liquid Chromatographic Method to Distinguish Wild Salmon From Aquacultured Salmon Fed Synthetic Astaxanthin", J. AOAC Int., 80(3): 622–632, 1997
Yang u. a., Cancer Res. 62, 2583–2591

Also Published As

Publication number Publication date
WO2015142705A1 (fr) 2015-09-24
KR20160144388A (ko) 2016-12-16
WO2015142707A1 (fr) 2015-09-24

Similar Documents

Publication Publication Date Title
US10624919B2 (en) Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9610313B2 (en) Eye health composition and method using plant derived seed extract rich in essential fatty acids derived from perilla seed and carotenoids
US9238043B2 (en) Composition and method to alleviate joint pain using algae based oils
DE202018105987U1 (de) Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
US20180289735A1 (en) Composition and method to alleviate joint pain using hyaluronic acid and eggshell membrane components
DE202010018054U1 (de) Zusammensetzung zur Linderung von Gelenkschmerzen
DE212015000076U1 (de) Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin
US20180042978A1 (en) Method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus
US20170281564A1 (en) Therapeutic astaxanthin and phospholipid composition and associated method
WO2015143001A1 (fr) Composition d'astaxanthine thérapeutique et de phospholipide et procédé associé
US20150231192A1 (en) Composition using seed oil extracts and phospholipids to enhance absorption of carotenoids and associated methods
US9974756B2 (en) Composition and method to alleviate joint pain using phospholipids and astaxanthin
WO2015175478A1 (fr) Composition employant des extraits d'huile de graines et des phospholipides pour améliorer l'absorption de caroténoïdes et procédés associés
WO2015142702A1 (fr) Composition et procédé pour soulager les douleurs articulaires au moyen de phospholipides et d'extrait d'œufs de poisson
US20170216383A1 (en) Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) peroxidation in humans using algae based oils and astaxanthin
DE202018105422U1 (de) Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
DE212015000073U1 (de) Zusammensetzung zum Mildern von Gelenkschmerzen mittels Phopholipiden und Astaxanthin
US9399047B2 (en) Composition and method to alleviate joint pain using phospholipids and roe extract
WO2019083732A1 (fr) Composition destinée au traitement de la fatigue oculaire photo-induite et de la réduction associée de vitesse de focalisation oculaire chez l'être humain

Legal Events

Date Code Title Description
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: A61K0031000000

Ipc: A61K0031728000

R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years
R151 Utility model maintained after payment of second maintenance fee after six years
R152 Utility model maintained after payment of third maintenance fee after eight years